Table 4.
Parameters | PFS-KM | PFS-Cox | OS-KM | OS-Cox | ||||||
Median survival (days) | p | Hazard ratio | p | Median survival (days) | p | Hazard ratio | p | |||
Group 0 | Group 1 | Group 0 | Group 1 | |||||||
Sex | 405 | 346 | 0.331 | 956 | 1610 | 0.685 | ||||
Age | 346 | 369 | 0.659 | 1610 | 1010 | 0.987 | ||||
Site of primary | 369 | 353 | 0.803 | 907 | 1709 | 0.069 | ||||
Haemoglobin | 564 | 366 | 0.474 | 776 | 1254 | 0.795 | ||||
White cell count | 373 | 286 | 0.241 | 1050 | 393 | 0.005 | 0.287 | 0.023 | ||
Platelets | 373 | 227 | 0.508 | 1610 | 105 | 0.000 | 0.531 | 0.187 | ||
ALP | 369 | 87 | 0.876 | 1050 | 941 | 0.556 | ||||
LDH | 426 | 327 | 0.020 | 0.685 | 0.158 | 1709 | 850 | 0.048 | 1.056 | 0.904 |
CEA | 428 | 339 | 0.049 | 0.858 | 0.571 | 1709 | 907 | 0.006 | 0.516 | 0.307 |
Number of mets | 428 | 316 | 0.006 | 0.540 | 0.022 | 1610 | 956 | 0.048 | 0.748 | 0.496 |
Surgery/RFA | 339 | 435 | 0.027 | 1.618 | 0.075 | 764 | 1807 | 0.000 | 6.119 | 0.001 |
Response to chemotherapy | 183 | 435 | 0.000 | 2.780 | <0.001 | 907 | 1050 | 0.135 | ||
Liver lesion diameter | 369 | 373 | 0.901 | 1807 | 941 | 0.031 | 1.404 | 0.606 |
ALP, alkaline phosphatase; CEA, carcionembryonic antigen; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; RFA, radiofrequency ablation.
After multivariate analysis, it was shown that number of metastases ≤2 and response to chemotherapy were associated with better PFS, whereas white cell count ≤10 and having received surgery or RFA to the liver metastases were associated with better OS.
Factors reaching statistical significance are highlighted in bold.